• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Dossier.org

Market Intelligence

  • About
    • How to structure intent in Memorandum of Understanding (MOU)
  • Market Dossier
    • Technology Dossier
    • Events
    • Venture Capital Dossier
  • Domain Dossier
  • Sponsored Post
    • Make a Contribution
  • Contact

Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

March 10, 2020 By admin Leave a Comment

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness (CEPI) awarded an initial funding of $4 million to support Novavax’ efforts to develop a COVID-19 vaccine. CEPI and Novavax are having ongoing discussions on additional funding from CEPI to address Novavax’ costs through Phase 1.

“This first stage of funding from CEPI is critical to enable ongoing development of our COVID-19 vaccine candidates,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We commend CEPI for its role as a vital partner to bridge the funding gap for innovative biotech companies like Novavax, which have robust vaccine technology platforms. Novavax is working tirelessly to create a vaccine against this growing epidemic.”

Novavax has produced and is currently assessing multiple recombinant nanoparticle vaccine candidates in animal models prior to advancing to clinical trials. Initiation of Phase1 clinical testing is expected in late spring of 2020. Novavax’ COVID-19 vaccine candidates were created with its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax also expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidates to enhance immune responses.

“The current crisis shows that we cannot prevent all infectious diseases from emerging. But we can and must double down on developing vaccines,” said Richard Hatchett, Chief Executive Officer of CEPI. “CEPI has moved quickly and urgently to coordinate with global health authorities and vaccine-development partners. CEPI is pleased to be partnering with Novavax to rapidly develop a potential vaccine candidate against the global threat posed by COVID-19.”

Novavax recently entered into an agreement with Emergent BioSolutions, Inc. (Emergent) to provide contract development and manufacturing services, supplying Novavax with vaccine product for preclinical testing and for use in its Phase 1 clinical trial. In addition, this arrangement offers the potential to leverage Emergent’s rapid deployment capabilities and expertise that provide Novavax scalability and capacity to produce vaccine product for future stockpiling. Emergent will utilize its two Baltimore, MD facilities to manufacture drug substance at its Bayview facility, designated by the U.S. Health and Human Services (HHS) as a Center for Innovation in Advanced Development and Manufacturing (CIADM), and drug product at its Camden facility.

About Coronavirus
A new strain of coronavirus first appeared in late 2019 in China before beginning its rapid spread across the globe. The disease, named COVID-19, continues to cause severe pneumonia-like symptoms in many of those infected. Coronaviruses, so named for their “crown-like” appearance, are a large family of viruses that spread from animals to humans and include diseases such as Middle East Respiratory Syndrome (MERS) and SARS in addition to COVID-19. While much remains unknown about the new coronavirus, it is known that the virus can spread via human-to-human transmission before any symptoms appear.

About Matrix-M™
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has reached over US$750 million of its $1 billion funding target. CEPI’s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (e.g. 2019-nCoV). To date, CEPI has committed to investing over $456 million in vaccine and platform development. Learn more at www.cepi.net.

About Novavax
Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine to demonstrate efficacy in a Phase 3 clinical trial. Novavax recently initiated development of a vaccine program against COVID-19. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs. For more information, visit www.novavax.com

Source: Novavax, Inc.

Filed Under: News Tagged With: COVID-19 Vaccine

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

VC

Plant-based food innovation company, TMRW Foods, raises C$2 million and prepares for North American launch with Sprouts Farmers Market
Biotech companies have received significant VC funding in the past three years
Upcoming Technology Conferences
Pulley Raises $40 Million Series B Led by Founders Fund
Seedtag raises over €250M from Advent International
Blues Wireless Raises $32M To Accelerate Enterprise Adoption of Cellular IoT
Clerk Announces $6.2M Seed Funding To Build Authentication And User Management Tools For React

Technologies

AWS Launches Second Infrastructure Region in India
Top Technology Trends of 2022
Securing position in global electric vehicle battery sector
Is Facebook losing its $100bn gamble on virtual reality?
How Cheap Hydrogen Could Become the Next Clean Fuel
5G is the New Cyber Attack Surface: Understanding the Risks and Opportunities
The Rise of Edge Computing: How It’s Changing the Way We Process Data

Secondary Sidebar

Analysis

China’s rapid reopening from COVID-19 has brought both joy and woe for world markets
T. ROWE PRICE 2022 MIDYEAR MARKET OUTLOOK: GLOBAL AND GEOPOLITICAL HEADWINDS LEAD FINANCIAL MARKETS TO INFLECTION POINT
CSCMP 2022 State of Logistics Report Indicates that Supply Chains Are Seeking to Get Back in Sync Amidst Rising Costs
The unemployment rate in the OECD fell further to 5.0% in April 2022, from 5.1% in March
Average Age of Vehicles in the US Increases to 12.2 years, according to S&P Global Mobility

Market Research

Will museums go digital?
MoscowRules.com (Moscow Rules): A Perfect Title for Publication Covering Russian Affairs
Media measurement services provide a holistic view of cross-media consumption
85% of marketers prefer visuals over text
CryptoExchange.Tokyo: Japan’s $1 trillion market for cryptocurrency trading

Footer

Recent Posts

  • Why UK faces chronic labor shortages
  • Battery Ventures Announces Sale of Physical-Security Technology Firm Qognify to Hexagon AB
  • impak Ratings acquires Exerica, a London-based fintech data extraction firm
  • Kentucky’s Wilderness Trail bourbon distillery to be sold to Italian maker of Campari
  • Container xChange Survey: 60% of Freight Forwarders and NVOCCs Struggle to Monitor Movement of Shipping Containers
  • Cloud storage company Box can surge nearly 40% on the future of work
  • Rockwell Automation Announces Intent to Acquire CUBIC
  • Vianode invests NOK 2 billion in battery materials plant in Norway
  • 69% of investors are betting the euro will slide to $0.9
  • Defense Market, July 2022

RSS Blockchaining

  • Blockchain topics to be covered at DLD 2023
  • Experience the Future of Blockchain at Cybertech 2023
  • Join Our Team as a Blockchain Developer - Revolutionize the Future
  • The Fascinating World of Cryptocurrency
  • State of Technology Overview: Blockchaining 2023

RSS S3H

  • Embracing Disruptive Innovation: The Key to a Better Future
  • The future of IoT and its impact on our lives and our world
  • Securing the Future: The Importance of Strong Cybersecurity
  • Cybertech 2023
  • Join Our Team at S3H.com Consulting - A One-Stop Shop for Technology Solutions

RSS VPNW

  • Unlock Your Creativity with a Competitive Mindset
  • Start today and make exercise a part of your daily routine
  • If hard work meant success, the donkey would own the farm
  • The Benefits of Mindfulness Meditation
  • The Rise of Plant-Based Diets

RSS OPINT

  • North Korea is working to create a nuclear warfighting capability
  • China’s proliferation of nuclear and missile-related technologies to other countries
  • The United States has been a major supporter of Ukraine’s security
  • The Impact of the Middle East on Global Geopolitics
  • The Impact of the Belt and Road Initiative on Global Geopolitics

Copyright © 2022 Dossier.org

Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT